Sanofi inks major AI deal to improve clinical development odds with $270M cash investment
For most of the up-and-coming AI players in the biotech space, we’ve seen a slew of deals to utilize AI and machine learning in drug discovery and manufacturing. Companies such as Insilico and Generate — just to name two — have been bagging partnerships and deals left and right.
Sanofi, though, has now lined up a new deal with one of the lower profile ops in Europe, going with a big investment with an eye to improving its odds in clinical development — and the biotech industry’s newest AI deal touts a new ingredient: federated learning.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.